Gene expression profiling in limb-girdle muscular dystrophy 2A

PLoS ONE

Volumn 3, Issue 11, 2008, Pages

  Sáenz, Amets ^a   Azpitarte, Margarita ^a   Armañanzas, Rubén ^b   Leturcq, France ^c   Alzualde, Ainhoa ^a   Inza, Iñaki ^b   García Bragado, Federico ^d   De la Herran, Gaspar ^a   Corcuera, Julián ^a   Cabello, Ana ^e   Navarro, Carmen ^f   De la Torre, Carolina ^g   Gallardo, Eduard ^g   Illa, Isabel ^g   de Munain, Adolfo López ^a  

^a HOSPITAL DONOSTIA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL DO MEIXOEIRO   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALPAIN 3; COLLAGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; FRIZZLED PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 32; MYC PROTEIN; MYOSIN; PROTEIN FOS; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG; WNT PROTEIN; CALPAIN; CAPN3 PROTEIN, HUMAN; FRZB PROTEIN; GLYCOPROTEIN; IL32 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MUSCLE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MUSCLE DEVELOPMENT; NEUTROPHIL CHEMOTAXIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RECESSIVE INHERITANCE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; AGED; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CALPAIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCLES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 56649091065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003750     Document Type: Article

References (60)

1. Sorimachi H, Imajoh-Ohmi S, Emori Y, Kawasaki H, Ohno S, et al. (1989) Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 264: 20106-20111.
2. Ono Y, Kakinuma K, Torii F, Irie A, Nakagawa K, et al. (2004) Possible regulation of the conventional calpain system by skeletal muscle-specific calpain, p94/calpain 3. J Biol Chem 279: 2761-2771.
3. Kinbara K, Sorimachi H, Ishiura S, Suzuki K (1998) Skeletal muscle-specific calpain, p94: structure and physiological function. Biochem Pharmacol 56: 415-420.
4. García Díaz BE, Gauthier S, Davies PL (2006) Ca2+ dependency of calpain 3 (p94) activation. Biochemistry 45: 3714-3722.
5. Sorimachi H, Kinbara K, Kimura S, Takahashi M, Ishiura S, et al. (1995) Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 270: 31158-31162.
6. Ono Y, Torii F, Ojima K, Doi N, Yoshioka K, et al. (2006) Suppressed disassembly of autolyzing p94/CAPN3 by N2A connectin/titin in a genetic reporter system. J Biol Chem 281: 18519-18531.
7. Hayashi C, Ono Y, Doi N, Kitamura F, Tagami M, et al. (2008) Multiple molecular interactions implicate connectin/titin N2A region as a modulating scaffold for p94/calpain 3 activity in skeletal muscle. J Biol Chem 283: 14801-14814.
8. Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, et al. (2005) Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet 13: 721-730.
9. Huang Y, de Morrée A, van Remoortere A, Bushby K, Frants RR, et al. (2008) Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 17: 1855-1866.
10. Guyon JR, Kudryashova E, Potts A, Dalkilic I, Brosius MA, et al. (2003) Calpain 3 cleaves filamin C and regulates its ability to interact with gamma- and delta-sarcoglycans. Muscle Nerve 28: 472-483.
11. Baghdiguian S, Martin M, Richard I, Pons F, Astier C, et al. (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 5: 503-511.
12. Baghdiguian S, Richard I, Martin M, Coopman P, Beckmann JS, et al. (2001) Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IkappaBalpha/NF-kappaB survival pathway in skeletal muscle. J Mol Med 79: 254-261.
13. Benayoun B, Baghdiguian S, Lajmanovich A, Bartoli M, Daniele N, et al. (2008) NF-kappaB-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J 22: 1521-1529.
14. Kramerova I, Kudryashova E, Tidball JG, Spencer MJ (2004) Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 13: 1373-1388.
15. Kramerova I, Kudryashova E, Venkatraman G, Spencer MJ (2005) Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 14: 2125-2134.
16. Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pécheux C, et al. (2006) CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 59: 905-911.
17. Arahata K, Ishihara T, Fukunaga H, Orimo S, Lee JH, et al. (1995) Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve 2: S56-66.
18. Weinstock A, Green C, Cohen BH, Prayson RA (1997) Becker muscular dystrophy presenting as eosinophilic inflammatory myopathy in an infant. J Child Neurol 12: 146-147.
19. Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, et al. (2001) Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57: 2136-2138.
20. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (2005) Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer.
21. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
22. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
23. Bolstad BM, Irizarry R A, Astrand M, Speed TP (2003) A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Bias and Variance. Bioinformatics 19: 185-193.
24. Haslett JN, Sanoudou D, Kho AT, Han M, Bennett RR, et al. (2003) Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 4: 163-171.
25. Bakay M, Chen YW, Borup R, Zhao P, Nagaraju K, et al. (2002) Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics 3: 4.
26. Duda RO, Hart PE, Stork DG (2000) Pattern classification. New York: Wiley-Interscience.
27. Kang PB, Kho AT, Sanoudou D, Haslett JN, Dow CP, et al. (2005) Variations in gene expression among different types of human skeletal muscle. Muscle Nerve 32: 483-491.
28. Wang Y, Tetko IV, Hall MA, Frank E, Facius A, et al. (2005) Gene selection from microarray data for cancer classification - a machine learning approach. Comput Biol Chem 29: 37-46.
29. Hall MA, Smith LA (1997) Feature Subset Selection: A Correlation Based Filter Approach, Proceedings of the Fourth International Conference on Neural Information Processing and Intelligent Information Systems, 855-858.
30. Chen YW, Zhao P, Borup R, Hoffman EP (2000) Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151: 1321-1336.
31. Campanaro S, Romualdi C, Fanin M, Celegato B, Pacchioni B, et al. (2002) Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet 11: 3283-3298.
32. Noguchi S, Tsukahara T, Fujita M, Kurokawa R, Tachikawa M, et al. (2003) cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet 12: 595-600.
33. Winokur ST, Chen YW, Masny PS, Martin JH, Ehmsen JT, et al. (2003) Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet 12: 2895-2907.
34. Taniguchi M, Kurahashi H, Noguchi S, Sese J, Okinaga T, et al. (2006) Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem Biophys Res Commun 342: 489-502.
35. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R (2007) Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68: 569-577.
36. Sáenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, et al. (2005) LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 128: 732-742.
37. von der Hagen M, Laval SH, Cree LM, Haldane F, Pocock M, et al. (2005) The differential gene expression profiles of proximal and distal muscle groups are altered in pre-pathological dysferlin-deficient mice. Neuromuscul Disord 15: 863-877.
38. Zhou X, Tan FK, Guo X, Arnett FC (2006) Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum 54: 2626-2631.
39. Karsch-Mizrachi I, Travis M, Blau H, Leinwand AL (1989) Expression and DNA sequence analysis of a human embryonic skeletal muscle myosin heavy chain gene. Nucleic Acids Res 17: 6167-6179.
40. Cohen N, Kudryashova E, Kramerova I, Anderson LV, Beckmann JS, et al. (2006) Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice. Proteomics 6: 6075-6084.
41. Marotta M, Sarria Y, Ruiz-Roig C, Munell F, Roig-Quilis M (2007) Laser microdissection-based expression analysis of key genes involved in muscle regeneration in mdx mice. Neuromuscul Disord 17: 707-718.
42. Baldwin KM, Haddad F (2002) Skeletal muscle plasticity: cellular and molecular responses to altered physical activity paradigms. Am J Phys Med Rehabil 81: S40-51.
43. Brancaccio M, Guazzone S, Menini N, Sibona E, Hirsch E, et al. (1999) Melusin is a new muscle-specific interactor for beta(1) integrin cytoplasmic domain. J Biol Chem 274: 29282-29288.
44. Kramerova I, Kudryashova E, Wu B, Spencer MJ (2006) Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation. Mol Cell Biol 26: 8437-8447.
45. Belkin AM, Zhidkova NI, Balzac F, Altruda F, Tomatis D, et al. (1996) Beta 1D integrin displaces the beta 1A isoform in striated muscles: localization at junctional structures and signaling potential in nonmuscle cells. J Cell Biol 132: 211-226.
46. Ono Y, Hayashi C, Doi N, Kitamura F, Shindo M, et al. (2007) Comprehensive survey of p94/calpain 3 substrates by comparative proteomics - possible regulation of protein synthesis by p94. Biotechnol J 2: 565-576.
47. Cyr DM, Langer T, Douglas MG (1994) DnaJ-like proteins: molecular chaperones and specific regulators of Hsp70. Trends Biochem Sci 19: 176-181.
48. Wu G, Liu C, He X (2004) Ozz: a new name on the long list of beta-catenin's nemeses. Mol Cell 13: 451-453.
49. Nastasi T, Bongiovanni A, Campos Y, Mann L, Toy JN, et al. (2004) Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev Cell 6: 269-282.
50. Frosk P, Weiler T, Nylen E, Sudha T, Greenberg CR, et al. (2002) Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 70: 663-672.
51. Figarella-Branger D, El-Dassouki M, Saenz A, Cobo AM, Malzac P, et al. (2002) Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. Neuromuscul Disord 12: 4-12.
52. Keira Y, Noguchi S, Kurokawa R, Fujita M, Minami N, et al. (2007) Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Neurosci Res 57: 513-521.
53. Olivé M, Martinez-Matos JA, Pirretas P, Povedano M, Navarro C, et al. (1997) Expression of myogenic regulatory factors (MRFs) in human neuromuscular disorders. Neuropathol Appl Neurobiol. 23: 475-482.
54. Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP, et al. (2008) Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol. 180: 1087-1100.
55. Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol 33: 637-668.
56. Campbell KP, Stull JT (2003) Skeletal muscle basement membrane-sarcolemma-cytoskeleton interaction minireview series. J Biol Chem 278: 12599-12600.
57. Ervasti JM (2003) Costameres: the Achilles' heel of Herculean muscle. J Biol Chem 278: 13591-13594.
58. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22: 131-142.
59. Dinarello CA, Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65: iii61-64.
60. Cai B, Spencer MJ, Nakamura G, Tseng-Ong L, Tidball JG (2000) Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol 156: 1789-1796.